郝海平 - 中国药科大学

个人简介

Education Background Aug 2012~Aug 2013, NIH/NCI, visiting scholar; Sep 2003~Jun 2006, China Pharmaceutical university, Ph.D of pharmacology; Sep 2000～Jun 2003, Nanjing University of Traditional Chinese Medicine, Master of TCM; Working Experience July 2015 to now, Dean of School of Pharmacy, China Pharmaceutical University; Jan 2013 to now, Associated Director of State Key Laboratory of Nature Medicine, China Pharmaceutical University; July 2011 to now, Key lab of Drug Metabolism & Pharmacokinetics, China Pharmaceutical University, Professor; Jun 2006~Jun 2011, Key lab of Drug Metabolism & Pharmacokinetics, China Pharmaceutical University, Associate Professor; Sep 1994~Aug 2000, Wangjiang Hospital of Traditional Chinese Medicine, Anhui Province, P.R. China, pharmacist of TCM.

研究领域

Focusing on metabolic regulation of endogenous substances, discovery and confirmation of drug targets, as well as mechanism of action for nature medicines, we have built systematic and universal quali-/quantitative methods for complex TCM components analysis, while providing theoretical and practical solution for studying of DMPK for nature medicine with multi-component and multi-target characteristics. Based on revealing the pattern for metabolism and disposition of natural active components by organism, we proposed theories of “Reverse Pharmacokinetics” and “DMPK-directed discovery of drug target and mechanism”, which have contributed to research of endogenous bioactive substances such bile acids and tryptophan.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hao H#, Cao L#, Jiang C#, Che Y, Zhang S, Takahashi S, Wang G*, Gonzalez FJ*. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metab. 2017 Apr 4;25(4):856-867.e5. Cao LJ#*, Che Y#, Meng T, Deng SS, Zhang J, Zhao M, Xu WF, Wang DD, Pu ZC, Wang GJ, Hao HP*. Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis associated colon cancer. Oncotarget. 2017, 8 (38): 63665-63679. Wang L#, Ye H#, Sun D, Meng T, Cao L, Wu M, Zhao M, Wang Y, Chen B, Xu X, Wang G*, Hao H*. A Metabolic Pathway Extension Approach for Metabolomic Biomarker Identification.Anal Chem. 2017 Jan 17;89(2):1229-1237. Wu M#, Ye H#, Shao C, Zheng X, Li Q, Wang L, Zhao M, Lu G, Chen B, Zhang J, Wang Y, Wang G*, Hao H*. Metabolomics-Proteomics Combined Approach Identifies Differential Metabolism-Associated Molecular Events between Senescence and Apoptosis. J Proteome Res. 2017 Jun 2;16(6):2250-2261. Zheng X, Zhang X, Wang G*, Hao H*. Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder. Drug Discov Today. 2015 May;20(5):562-8. Zhou X, Cao L, Jiang C, Xie Y, Chen X, Krausz KW, Qi Y, Sun L, Shah YM, Gonzalez FJ, Wang G*, Hao H*. PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun, 2014, 5:4573. Hao H, Zheng X, Wang G*. Insights to drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharmacol Sci, 2014, 35(4):168-177.